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SCLEROTHERAPY PLUS OCTREOTIDE VERSUS SCLEROTHERAPY 
ALONE IN THE MANAGEMENT OF GASTRO-OESOPHAGEAL 
VARICEAL HEMORRHAGE 
Hasnain A. Shah, Khalid Mumtaz, Wasim Jafri, Shahab Abid, Saeed Hamid, 
Ashfaq Ahmad, Zaigham Abbas 
Section of Gastroenterology, Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan 
Background: There are different ways for controlling oesophageal variceal bleed which include 
pharmacological and endoscopic methods. In this study we compare efficacy of octreotide (50 g/hr 
for 48 hours) combined with sclerotherapy versus sclerotherapy alone in patients with acute bleeding 
from gastro-oesophageal varices (GOV). Methods: It was a randomized clinical controlled trial 
conducted at Aga Khan University Hospital, Karachi, from January1997 to December 1998. We 
evaluated the role of octreotide (50 g/hr for 48 hours) combined with sclerotherapy versus 
sclerotherapy alone in a total of 105 adult cirrhotic patients who had acute bleeding from GOV. 
Patients were assigned to receive octreotide plus sclerotherapy or sclerotherapy alone. Primary 
outcome measure was 5-day survival without rebleeding. The hospital stay in days and blood 
transfusion requirements were also compared in the combined treatment group versus sclerotherapy 
alone group. Results: Initial control of bleeding was achieved in 46/51 (90.2%) patients who received 
combined treatment compared to 41/54 (75.9%) patients (p=0.05) in sclerotherapy alone group. 
Rebleeding after the first 48 hours was less in the octreotide treated patients 2/46 vs. 8/41 patients 
(p=0.003). The octreotide treated patients had a better short term (5 days) survival without rebleeding 
44/51 vs. 33/54 (p=0.003) and shorter hospital stay, 5.31 ± 3.87 days vs. 6.63 ± 3.86 (p=0.008) as 
compared to sclerotherapy alone group.  The blood transfusion requirement was also less in the 
combined treatment group 3.88 ± 2.80 vs. 5.37 ± 3.15 units (p=0.002). Conclusion:  1) The 
combination of sclerotherapy and octreotide infusion over 48 hours is more effective than 
sclerotherapy alone in the treatment of acute variceal bleeding and prevention of early rebleed in 
cirrhotic patients.  2) It leads to shorter hospital stay and 3) less blood transfusion requirements. 4) 
Although early survival without rebleeding is improved, the overall mortality at the end of 
hospitalization period is similar in the two groups of treated patients. 
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INTRODUCTION 
Hemorrhage from gastroesophageal varices is an important complication of portal hypertension due to cirrhosis of liver. 
Despite the improvements in therapeutic techniques employed in the management of acutely bleeding varices, the 
mortality remains in the range of 30-50% 1-6. Sclerotherapy is considered an efficient modality of treating acutely 
bleeding varices in most institutions of the world 7. The effectiveness of this technique depends on the availability of 
well-trained personnel and sophisticated instruments. 
Bleeding is controlled in the short term in upto 90% of patients 8, 9. The rate of rebleeding in such patients is 
high, upto 50% in the short term following admission. It has therefore been recommended that treatment for variceal 
bleed should not only be aimed at arresting the acute bleed but also at preventing early rebleed and thus improving 
morbidity and mortality. Various techniques have been used in the treatment of variceal hemorrhage including 
pharmacological measures, balloon tamponade, band ligation of varices; trans-jugular intra-hepatic portosystemic shunts 
(TIPSS) and emergency surgery apart from sclerotherapy.  Combination of various procedures have also been tried so as 
to improve outcome in acutely bleeding patients. 
Octreotide is a synthetic somatostatin analogue which is a potent vasoconstrictor agent in the splanchnic 
circulation without any significant systemic hemodynamic effects and has been used to control hemorrhage from 
ruptured gastroesophageal varices. Reduction in portal pressure after octreotide has been shown 10 and a decrease in 
azygos blood flow in patients with cirrhosis has also been consistently reported.11-13 Octreotide has been compared 
with balloon tamponade 10, Vasopressin 14, Glypressin 15, 16 and sclerotherapy 17, 18. Two recent studies, 19, 20 on the 
use of octreotide in combination with sclerotherapy in an attempt to improve outcome in the acutely bleeding 
patients have shown encouraging results. The available literature has used octreotide for a longer time period (5 
days) in an attempt to improve outcome in the acutely bleeding varices. There is paucity in literature on short term 
use of octreotide (48 hours) in the treatment of acute gastro-oesophageal variceal bleed 21.   
In a randomized study, we have compared sclerotherapy alone with a combination of sclerotherapy and 
octreotide infused over 48 hours in controlling acute variceal bleed and preventing early rebleeding in patients with 
cirrhosis of liver. 
MATERIAL AND METHODS 
This study was conducted at Aga Khan University Hospital (AKUH), Karachi from January 1997 to December 1998. It 
was a randomized clinical controlled trial. A total of 105 patients were enrolled into the study. Fifty-one patients received 
octreotide plus sclerotherapy whereas 54 patients received sclerotherapy treatment alone. 
All adult patients admitted to the AKUH with a history of hematemesis or melena (or both) within 24 hours 
prior to admission were evaluated. Cirrhosis of the liver had either been diagnosed previously or on current admission on 
the basis of clinical signs of chronic liver disease such as ascites, palmar erythema, spider angiomas, splenomegaly and 
biochemical evidence of derangement of liver function, abdominal ultrasound and / or liver biopsy where possible. 
An upper gastrointestinal endoscopy was done within 12 hours of admission, following resuscitation. Patients 
were enrolled in the trial if they were found to have active esophageal variceal bleeding; active esophageal variceal 
bleeding was taken as spurt or ooze from a varix seen at endoscopy. Non-bleeding esophageal varices with signs of 
recent bleed in the upper gastrointestinal tract like presence of blood, red marks on varices and no other source of upper 
gastrointestinal bleed were also enrolled. 
Patients were excluded from the study if they had had previous sclerotherapy within the last eight days; 
evidence of severe liver failure i.e. prothrombin time greater than 10 seconds prolong, serum albumin less than 1.5 grams 
per d/l, serum bilirubin greater than 5 mg% and / or significant impairment of renal function i.e. serum creatinine greater 
than 4 mg%. Age above 85 years and non-cirrhotic portal hypertension were also considered as exclusion criteria. 
A complete blood count including hemoglobin, white blood cell count, platelet count, and hematocrit, blood 
urea nitrogen, serum creatinine, blood sugar and electrolytes were done initially and repeated if needed during hospital 
stay of patients. Liver function tests of all patients were also done on admission to assess the degree of impairment of 
liver function. Endoscopic esophageal variceal sclerotherapy was performed with 3-5 ml of 5% injection ethanolamine 
oleate per varix (total of 20 ml) during initial endoscopy. Randomization was carried out after initial endoscopy. A 
sealed envelope containing the treatment option was opened and treatment given accordingly. Patients were distributed 
in two arms; one arm was given octreotide infusion in a dose of 50 mcg/hr and other was started on normal saline 
infusion as placebo for 48 hours in a randomized manner. Supportive measures like lactulose, I/V fluids, oxygen etc 
were administered where indicated. Both groups received packed cells and / or fresh frozen plasma as and when 
required. We did not injected the cardia varix as they were not actively bleeding. 
Patients, who rebled evidenced by a drop in systolic BP of > 20 mm Hg with a rise in pulse rate of > 
110/minute or a drop in > 2 gm of hemoglobin, were re-endoscoped and repeat sclerotherapy done. Failure of control of 
bleeding following second sclerotherapy session led to surgical referral and emergency surgery where possible. 
The primary outcome measure was survival without rebleeding at 5 days after sclerotherapy which was taken as 
either control of acute variceal bleeding, without rebleeding or death. The other end points were to determine the blood 
transfusion requirements following endoscopy and difference in hospital stay in the two groups of treated patients. 
Variceal bleeding was considered to have been controlled, if the blood pressure stabilized and there was no drop in 
systolic blood pressure exceeding 20 mmHg (supine) and the hemoglobin concentration and hematocrit also stayed 
stable after the initial control of hemostasis. 
Statistical analysis was performed on all patients who underwent randomization. The two treatment groups 
were compared on the basis of primary outcome measure using Mantel-Haenszel test. Various prognostic variables were 
tested against the primary outcome measure using Mantel-Haenszel test and Pearson’s Chi Square test wherever 
appropriate and difference of means was compared by using independent sample t-test. All p values were two tailed, p 
values of equal to or less than 0.05 were considered to indicate statistical significance. Analysis was performed using 
SPSS 10.0 version. 
This study was approved by the ethical review committee of AKUH and any ethical concern was dealt before 
the start of study. Patients were allocated to sclerotherapy along with octreotide and sclerotherapy with placebo (normal 
saline) by simple sealed envelope randomization containing the treatment groups on one to one basis to reduce 
possibility of bias. There was no conflict of interest among any of the authors. 
RESULTS 
A total of 105 patients were enrolled into the study after the inclusion and exclusion criteria were met. Fifty-one patients 
received octreotide plus sclerotherapy whereas 54 patients received sclerotherapy treatment alone. The two groups had 
similar baseline characteristics (table 1). The mean total dose of 5% ethanolamine oleate injected per patient was also 
similar in the two groups. Twenty-four patients in the combined treatment group and 27 in the sclerotherapy alone 
treated group had inactive bleeding at initial endoscopy, respectively. After five days, the proportion of patients who had 
survived without rebleeding was significantly higher in the octreotide treated group, 44 of 51 patients (86.82%) vs. 33/54 
(61.1%) in the sclerotherapy alone group; p=0.003 (table 2). Similarly, the rate of survival at five days without 
rebleeding was higher in the octreotide treated patients than in the sclerotherapy alone, group when the data were 
analyzed according to the Child-Pugh class of hepatic function. However, the difference was not statistically significant 
in the Child-Pugh class A patients (table 2). The difference in survival remained significant after simultaneous 
adjustment for the Child-Pugh class of hepatic function, the presence or absence of acute bleeding at initial endoscopy, 
and previous treatment with propranolol or the absence of such treatment, sex, hemoglobin, and creatinine (p=0.001 by 
the Mantel-Haenszel test). In patients who rebled after the initial control of bleeding, 2 in combined treatment and 8 in 
sclerotherapy alone underwent re-secelrotherapy; none in the combined group and 2 in the sclerotherapy group were 
referred for surgery. 
 
 
Table 1: Demographic features in two Study Groups 
Characteristics Sclerotherapy + Octreotide 
(n=51) 
Sclerotherapy alone 
(n=54) 
Age            Mean (yrs) 
Sex            (M:F) 
Etiology:  Viral 
                  Alcoholic 
Child pugh class  A 
                                B 
                                C 
Active EV bleed 
Gastric Varices 
Hepatic Encephalopathy 
                Absent 
                Stage I-II 
                Stage III-IV 
Bilirubin    (mg/dl) 
Albumin    (gm/dl) 
Creatinine (mg/dl) 
Prothrombin Time (Secs. Prolonged) 
Hemoglobin (gm%) 
Interval b/w start of bleeding & 
endoscopy 
Previous Propranolol therapy 
49.5 14.2 
32:19 
49 
02 
09 
31 
11 
23 
04 
  
33 
15 
02 
1.44  0.83 
2.49  0.61 
1.12  0.44 
3.73  1.56 
8.54  1.97 
All within 24 hrs 
  
17 
50  12.3 
36:18 
52 
02 
07 
33 
14 
24 
03 
  
38 
14 
02 
1.85  0.90 
2.34  0.53 
1.29  0.68 
4.28  2.17 
8.92  1.75 
All within 24 hrs. 
  
15 
Table 2: Comparison of Outcomes in the Two Study Groups 
Outcomes Sclerotherapy + 
Octreotide n=51 (%) 
Sclerotherapy alone 
n=54 (%) 
p-values 
Controlled bleeding in 24 hrs. 
Rebleeding b/w 24 hrs – 5 days 
Controlled bleeding during hospital stay 
Survival without rebleeding @ 5 days 
Child pugh class: 
                        A 
                        B 
                        C 
Total blood transfusions: (Units) 
46 (90.2%) 
02 (3.9%) 
37 (72.5%) 
  
44 (86.3%) 
  
08/09 
27/31 
09/11 
41 (76%) 
08 (14.8%) 
28 (51.8%) 
  
33 (61%) 
  
06/07 
22/33 
05/14 
0.05 
0.003 
0.03 
  
0.003 
  
- 
- 
0.05 
Death with uncontrolled bleeding 
Death with controlled bleeding 
Hospital Stay ( days)        
3.88  2.80 
07 (13.7%) 
03 (5.8%) 
5.31  3.87 
5.37  3.15 
09 (16.6%) 
03 (5.5%) 
6.63  3.86 
0.002 
NS 
NS 
0.008 
NS= Not Significant 
 
 
The total number of units of blood transfused during hospital stay of the patients following endoscopy was 
significantly less in the octreotide treated patients than the sclerotherapy group (mean no. of units 3.88 ± 2.80 vs. 5.37 ± 
3.15; p=0.002). The hospital stay was similarly shorter in the octreotide treated patients than sclerotherapy alone treated 
patients (5.31 ± 3.87 days vs. 6.63 ± 3.86 days; p=0.008). 
 
 
Logistic regression analysis, incorporating all the characteristics in table 1 indicated that the factors 
independently associated with survival without rebleeding at 5 days were the treatment assigned (p=0.002) and the 
presence of active esophageal variceal bleeding (p=0.02). 
DISCUSSION 
Bleeding from gastroesophageal varices is associated with a major risk of death.22,23 Currently available modalities of 
treatment such as sclerotherapy help control bleeding in up to 90% of patients.8, 10 However, the risk of rebleeding and 
complications is high. Hence, there is a need for use of adjuvant measures to improve the mortality rate as well as 
decrease the risk of rebleeding in cirrhotic patients. 
In this, randomized clinical trial involving 105 patients, we have evaluated efficacy of octreotide infusion given 
to 51 patients intravenously for short period (48 hours), following sclerotherapy for the control of acute gastroesophageal 
variceal bleeding in a group of patients suffering from cirrhosis of the liver, mostly (96%) due to viral causes. Octreotide 
treated group was seen to be associated with a significantly higher rate of survival without rebleeding at 5 days compared 
to the sclerotherapy alone group. This finding has been demonstrated in other studies but most of these studies have used 
octreotide infusion for 5 days.24-26 In our setting where cost constraint is a major problem, short duration of octreotide 
infusion as shown in our study, can be as effective as 5 day treatment. The difference in control of bleeding and 
rebleeding is statistically significant, however, only in the child B and C class of patients. This is because such patients 
are at a higher risk of rebleed than child A class of patients and more likely to benefit from an adjuvant treatment. The 
overall death rate at the end of the hospitalization period is however similar in the two groups of treated patients (Table 
2).  This means that octreotide use for a 48 hours period did not significantly alter the course of events after the first 5 
days following start of treatment. 
We have used octreotide intravenously as an infusion for a 48 hour period following sclerotherapy.  Besson et 
al19 and Zuberi and Baloch 20 in their published studies have maintained the infusion for five days. This length of time 
would increase the cost of patient care and add to the burden on health care resources of the unit, in a third world country 
like Pakistan by a large proportion. We have shown that using the medication for a shorter period maintains the benefit 
of control of bleeding after discontinuation of treatment. This may be because the risk of rebleed is maximal in the first 
48 hours after a bleed and declines thereafter22,23. In a study reported from Peshawar27 author has compared octreotide 
alone in a dose of 25 ug / hour infusion followed by 50 ug / hour for another 48 hour, with injection sclerotherapy which 
is found effective in only first 24 hours but not at all beyond that point although the treatment was given for 3 days. In 
this study every 6th patient would need sclerotherapy after 24 hours along with a possibility to restart vasoactive 
substance which can be expensive, time consuming approach rather than a cost effective way. 
The blood transfusion requirement as well as hospital stay of the surviving patients is also decreased in our study, when 
octreotide is used for only 48 hours as compared to other study where it is used for five or more days.28 This is of 
tremendous importance in situations where blood and blood products as well as hospital beds are in short supply. 
Our study has clearly demonstrated benefit of a short term pharmacological therapy in conjunction with 
injection sclerotherapy, which is simple to use, devoid of major side effects, relatively cheap and non-invasive in a 
patient care area where a lot of work is being done worldwide to find ways and means of improving outcome following 
treatment. There is still a need to devise adjuvant treatment to be used with sclerotherapy, which could improve late 
mortality following gastroesophageal variceal bleed. 
CONCLUSIONS 
•         Octreotide infusion for 48 hours in conjunction with injection sclerotherapy compared with sclerotherapy alone 
improves initial control of bleeding and bleeds free survival at five days. 
•         There is significant decrease in the requirement of packed red blood cells and blood product transfusions in patients 
where octreotide is used as an adjunct treatment along with injection sclerotherapy. 
•         Combination of octreotide with sclerotherapy leads to shorter hospital stay as compared to sclerotherapy alone 
treatment. 
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